Certara, Inc. (CERT)
NASDAQ:CERT
Want to see CERT full AI Analyst Report?
CERT Stock Chart & Stats
$6.22
-$0.37(-3.29%)
At close: 4:00 PM EST
$6.22
-$0.37(-3.29%)
Day’s Range― - ―
52-Week Range$4.45 - $13.88
Previous CloseN/A
Volume176.64K
Average Volume (3M)4.44M
Market Cap
$840.05M
Enterprise Value$1.09B
Total Cash (Recent Filing)$149.48M
Total Debt (Recent Filing)$300.26M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Aug 11, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding155,564,600
10 Day Avg. Volume5,050,995
30 Day Avg. Volume4,442,557
Financial Highlights & Ratios
PEG Ratio10.16
Price to Book (P/B)1.33
Price to Sales (P/S)3.37
P/FCF Ratio14.94
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue2.59
Enterprise Value/Gross Profit4.46
Enterprise Value/Ebitda10.75
Forecast
1Y Price Target
$7.81Price Target Upside25.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)0.38
Revenue Forecast (FY)$398.41M
Bulls Say, Bears Say
Bulls Say
Very Low Leverage And Conservative Balance SheetCertara’s balance sheet is structurally strong: debt-to-equity near 0.01 and about $1.0B equity provide durable financial flexibility to fund R&D, M&A or buybacks without reliance on external financing, reducing refinancing and liquidity risk over the next several quarters.
Recurring Software Revenue, Strong Bookings And RetentionHigh software net retention (106%), rising bookings and a majority of ratable subscription revenue support predictable recurring cash flows and scalable margins. This durable shift toward subscription software underpins long-term revenue visibility and higher margin potential compared with project-based services.
Consistent Operating And Free Cash Flow GenerationSustained positive operating and free cash flow historically indicate genuine cash-generative operations. Even with recent FCF decline, ongoing positive cash conversion supports reinvestment, debt reduction and capital returns, making cash generation a durable pillar for financing growth and improving profitability.
Bears Say
GAAP Net Losses And Volatile ProfitabilityRepeated GAAP losses and profit volatility signal that improving bottom-line results remains uncertain. Until management sustains positive net income, return on equity will remain weak and the company’s ability to convert growing revenues into durable shareholder earnings is limited over the medium term.
Services Revenue Weakness And Go-to-market Execution GapsSoftness in services and booking declines reflect structural go-to-market and execution challenges that can limit cross-sell and pipeline conversion. Given services remain ~50% of revenue, sustained weakness constrains overall revenue growth and complicates margin improvement despite software strength.
Transition Risk From Divestiture, Reorg And Higher Operating CostsThe strategic divestiture and reorganization aim to sharpen focus but introduce execution risk, operational churn and near-term cost volatility. Rising operating expenses and acquisition-related charges can depress margins before expected benefits from refocusing and AI investments materialize.
Certara News
CERT FAQ
What was Certara, Inc.’s price range in the past 12 months?
Certara, Inc. lowest stock price was $4.45 and its highest was $13.88 in the past 12 months.
What is Certara, Inc.’s market cap?
Certara, Inc.’s market cap is $840.05M.
When is Certara, Inc.’s upcoming earnings report date?
Certara, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 47 days.
How were Certara, Inc.’s earnings last quarter?
Certara, Inc. released its earnings results on May 11, 2026. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.106 by -$0.016.
Is Certara, Inc. overvalued?
According to Wall Street analysts Certara, Inc.’s price is currently Undervalued.
Does Certara, Inc. pay dividends?
Certara, Inc. does not currently pay dividends.
What is Certara, Inc.’s EPS estimate?
Certara, Inc.’s EPS estimate is 0.1.
How many shares outstanding does Certara, Inc. have?
Certara, Inc. has 155,564,600 shares outstanding.
What happened to Certara, Inc.’s price movement after its last earnings report?
Certara, Inc. reported an EPS of $0.09 in its last earnings report, missing expectations of $0.106. Following the earnings report the stock price went down -18.7%.
Which hedge fund is a major shareholder of Certara, Inc.?
Currently, no hedge funds are holding shares in CERT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Certara Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.81 (25.60% Upside)
$7.81 (25.60% Upside)
Blogger Sentiment
Bullish
CERT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 133.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.37%
12-Months-Change
Fundamentals
Return on Equity
-1.43%
Trailing 12-Months
Asset Growth
-3.88%
Trailing 12-Months
Company Description
Certara, Inc.
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.
CERT Company Deck
CERT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive outlook: software performance, strong software bookings, high net retention, regulatory qualifications and strategic AI/partnership initiatives are clear positives that support longer-term growth potential. However, services softness, quarter-to-quarter execution issues, a GAAP net loss and declines in adjusted profitability and EPS are tangible near-term negatives. Management is pursuing structural changes (divestiture, reorg, AI platform and partnerships) to address execution gaps and to reposition the company for scaling, but these actions introduce short-term transition risk.View all CERT earnings summariesCERT Stock 12 Month Forecast
Average Price Target
$7.81
▲(25.60% Upside)
Technical Analysis
Omnicell
―
Health Catalyst
―
Schrodinger
―
SOPHiA GENETICS
―
Definitive Healthcare Corp
―
Ownership Overview
2.52% Insiders
17.60% Mutual Funds
26.95% Other Institutional Investors
33.51% Public Companies and
Individual Investors